XML 17 R6.htm IDEA: XBRL DOCUMENT v2.4.0.8
STATEMENTS OF CASH FLOWS (USD $)
6 Months Ended
Aug. 31, 2013
Aug. 31, 2012
CASH FLOWS FROM OPERATING ACTIVITIES    
Net loss $ (2,463,556) $ (3,474,201)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation 342 342
FDA clinical trial expenses paid directly by S.R. Burzynski, M.D., Ph.D. 2,119,432 2,902,548
Warrants issued for services   159,896
Changes in operating assets and liabilities    
Accounts payable 105,532 (1,687)
Accrued liabilities (14,996) (14,750)
NET CASH USED IN OPERATING ACTIVITIES (253,246) (427,852)
CASH FLOWS FROM FINANCING ACTIVITIES    
Contribution of capital 252,900 424,682
NET CASH PROVIDED BY FINANCING ACTIVITIES 252,900 424,682
NET DECREASE IN CASH (346) (3,170)
CASH AT BEGINNING OF PERIOD 1,192 17,297
CASH AT END OF PERIOD $ 846 $ 14,127